Sponsored by GSK US Medical AffairsIn this disease education video series from GSK, leading rheumatologists and nephrologists share their perspectives on lupus nephritis and reflect upon the gaps that remain in our understanding and management of the disease.
May 03, 2021
Sponsored by Novartis Medical AffairsListen to Ethan Craig, MD, MPH discuss 3 of his patient cases to identify and differentiate axial involvement within the spectrum of spondyloarthritis.
Apr 06, 2021
Sponsored by Novartis Medical AffairsListen to a discussion of medical experts share their views on the most impactful work done in Spondyloarthritis and Still’s Disease in 2020.
Mar 08, 2021
SELECT-COMPARE and SELECT-CHOICE: Evaluating Head-to-Head Trials to Help Inform Treatment Decisions in RA
Sponsored by AbbVie Medical Affairs
Feb 01, 2021
Sponsored by Novartis Medical Affairs
Jan 01, 2021
Head-to-Head Study of Upadacitinib vs Abatacept in Patients with RA and Inadequate Response to Biologics: Results from SELECT-CHOICE
Sponsored by AbbVie US Medical AffairsYour patient with rheumatoid arthritis has not responded to their biologic DMARD – now what? This article highlights the results from SELECT-CHOICE, which is the second head-to-head Phase 3 trial of the JAK inhibitor, upadacitinib, in RA. In this study, upadacitinib was evaluated for noninferiority and superiority assessments vs abatacept, in patients with moderate-to-severe RA who had prior inadequate response to biologic DMARD(s).
Nov 01, 2020
Sponsored by AbbVie US Medical AffairsPatients with axial spondyloarthritis (axSpA) present with a wide range of symptoms. Given the disease’s heterogeneous presentation, what tools can be used to monitor patients with axSpA and their response to treatment? How can symptoms be tracked and analyzed over time? This article examines some commonly used axSpA disease measures, moving them from esoteric concepts to practical tools for understanding clinical trials and use in everyday practice.
Oct 01, 2020
Sponsored By AbbVie Medical AffairsAddressing the heterogeneous manifestations of psoriatic arthritis (PsA) can be challenging for physicians. But how is disease control defined in PsA? What are appropriate treatment targets for use in clinical practice? Join Dr. Alexis Ogdie and Dr. Philip Mease for an overview of composite measures used to assess disease activity and ongoing discussions surrounding disease control and treatment targets for patients with PsA.
Sep 01, 2020
Sponsored By AbbVie Medical AffairsHow do you measure remission in your patients with RA? There are multiple composite measures that can be reliably utilized in clinical practice to assess disease activity and remission. This article highlights these measures and how treatment with upadacitinib, with or without MTX, was assessed across multiple measures of remission in the SELECT program.
Aug 01, 2020
Safety Profile of RINVOQ™ (upadacitinib): Analysis of Up to ~3.5 Years of Exposure in Patients With Rheumatoid Arthritis
Sponsored by AbbVie Medical AffairsPresented here is an update on the longer-term safety profile of upadacitinib, drawing on the integrated analysis of up to ~3.5 years of exposure data from five Phase 3 studies. Dr. Winthrop and Dr. Cush provide additional information from relevant EULAR 2020 posters.
Jul 01, 2020